Skip to content

Home
Immuno-Oncology
Therapies
- Approved Drugs
- Experimental Therapies
  - a
    - ABBV-181
    - ABBV-428
    - ABP798
    - Actimmune
    - Adagloxad Simolenin
    - ADU-741 (JNJ-64041809 )
    - ADXS-HER2
    - ADXS-PSA
    - AE37
    - AFM11
    - AFM13
    - AGEN1884
    - AGEN2034
    - ALKS 4230
    - AlloStim
    - AM0010 (Pegilodecakin)
    - AMG 211 (MEDI-565)
    - AMG 330
    - AMG 420
    - APVO414 (MOR209/ES414)
    - AST-VAC1
    - ATA520
    - AutoSynVax
  - b-c
  - D-F
  - G-I
    - GALE-301
    - Galinpepimut-S
    - Ganitumab
    - GBR 1342
    - GI-6207
    - GI-6301
    - GL-ONC1
    - Gliovac (ERC1671)
    - GP2
    - GRN-1201
    - GSK3174998
    - GWN323
    - HF10
    - ICT-107
    - ICT-121
    - IGN002
    - IMCgp100
    - IMP701
    - INCAGN1949
    - INO-1400
    - INO-3106
    - INO-5150
    - INO-9012
  - J-L
  - M-O
    - M7824
    - MAGE-A10 T-Cell Therapy
    - MBG453
    - MDNA55
    - MEDI0457
    - MEDI0562
    - MEDI0680
    - MGA012
    - MGD009
    - MK-4166
    - Mogamulizumab
    - MVA-BN Brachyury
    - MVI-118
    - NEO-PV-01
    - NeuVax (Nelipepimut-S)
    - NKR-2
    - NKTR-214
    - NY-ESO TCR
    - OncoVAX
    - ONCOS-102
    - Opdivo (Nivolumab)
  - P-S
    - PAN-301-1
    - PDR001
    - PDS0101
    - PF-04518600
    - PF-06801591
    - PNK-007
    - ProscaVax
    - Provenge (Sipuleucel-T)
    - PVRIG
    - REGN2810 (SAR439684)
    - REGN3767
    - Relatlimab
    - Reolysin
    - RG7802
    - RG7828
    - Rocapuldencel-T
    - rSIFN-co
    - SHR-1210
    - SL-701
    - SurVaxM
  - T-Z
    - TT12
    - Tedopi (OSE-2101)
    - Telomelysin (OBP-301)
    - TG4010
    - TPIV 200
    - TPIV200
    - Traumakine
    - TRX518
    - TSR-022
    - TSR-042
    - Utomilumab
    - ValloVax
    - Varlilumab
    - VBI-1901
    - VGX-3100
    - Viagenpumatucel-L
    - Vigil
    - VX15
    - XmAb13676
Categories

Search for:

Register

Home » Register

Start a subscription

Please go to the subscribe page to choose a subscription level.

Subscription Support

Search for:

Create your own user feedback survey

Featured Posts

FDA Grants Priority Review to Opdivo-Yervoy Combo as First-Line Treatment for Advanced NSCLC

January 20, 2020

Dosing Begins in Study of Immune Checkpoint Inhibitor, Alone or in Combo, for Solid Tumors

January 15, 2020

Adding BL-8040 to Keytruda and Chemo Shows Good Disease Control in Pancreatic Cancer, Phase 2 Trial Shows

December 18, 2019

Visit Immuno-Oncology News's profile on Pinterest.

Immuno-Oncology News

BioNews Services, LLC

1601 Market St.
Suite 20B103
Philadelphia, PA 19103
Email: [email protected]
Phone: 1-800-936-1363

About Immuno-Oncology News
Our Team
Our Guiding Ethics
Keytruda (Pembrolizumab)
Contact Us
Privacy Policy
Terms of Service
Disable Notifications

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Start a subscription

Pin It on Pinterest